Advances in the study of SARS-CoV-2 related nerve invasiveness

doi:10.3877/cma.j.issn.2095-123X.2020.03.009

Abstract

Abstract:

There is increasing evidence that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can not only damage the respiratory tract, but also invade the central nervous system and induce nervous system diseases. SARS-CoV-2, as an emerging virus, may have both short-term and long-term effects on the nervous system. In addition, the current clinical treatment of SARS-CoV-2 is limited to symptomatic support therapy and the use of a variety of anti-RNA viral drugs (e.g., farapiravir, hydroxychloroquine). Although vaccines and therapeutic antibodies specifically targeted at SARS-CoV-2 are also being tested, this solution is long-term because they require thorough testing of their safety. Therefore, it is particularly important to understand the potential nerve invasion mechanism of SARS-CoV-2, which has important guiding significance for its prevention and treatment. This article reviews the etiology of SARS-CoV-2, the possible mechanism of nerve invasion, and its relationship with nervous system diseases, in order to provide evidence and reference for the effective prevention and treatment of SARS-CoV-2.

Key words: Severe acute respiratory syndrome coronavirus 2, Coronaviruses infection, Central nervous system, Neurological

Hongkun Liu, Wenbin Zheng. Advances in the study of SARS-CoV-2 related nerve invasiveness[J]. Chinese Journal of Brain Diseases and Rehabilitation(Electronic Edition), 2020, 10(03): 169-173.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhnkjbykfzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-123X.2020.03.009

https://zhnkjbykfzz.cma-cmc.com.cn/EN/Y2020/V10/I03/169

References 41

[1]	Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China[J]. JAMA Neurol, 2020, 77(6): 683-690.
[2]	Corman VM, Lienau J, Witzenrath M. Coronaviruses as the cause of respiratory infections[J]. Internist (Berl), 2019, 60(11): 1136-1145.
[3]	Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding[J]. Lancet, 2020, 395(10224): 565-574.
[4]	Mengeling WL, Boothe AD, Ritchie AE. Characteristics of a coronavirus (strain 67N) of pigs[J]. Am J Vet Res, 1972, 33(2): 297-308.
[5]	Li YC, Bai WZ, Hirano N, et al. Coronavirus infection of rat dorsal root ganglia: ultrastructural characterization of viral replication, transfer, and the early response of satellite cells[J]. Virus Res, 2012, 163(2): 628-635.
[6]	Andries K, Pensaert MB. Immunofluorescence studies on the pathogenesis of hemagglutinating encephalomyelitis virus infection in pigs after oronasal inoculation[J]. Am J Vet Res, 1980, 41(9): 1372-1378.
[7]	Li YC, Bai WZ, Hirano N, et al. Neurotropic virus tracing suggests a membranous-coating-mediated mechanism for transsynaptic communication[J]. J Comp Neurol, 2013, 521(1): 203-212.
[8]	Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin[J]. Nature, 2020, 579(7798): 270-273.
[9]	Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation[J]. Science, 2020, 367(6483): 1260-1263.
[10]	Xu X, Chen P, Wang J, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission[J]. Sci China Life Sci, 2020, 63(3): 457-460.
[11]	Walls AC, Park YJ, Tortorici MA, et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein[J]. Cell, 2020, 181(2): 281-292.e286.
[12]	Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor[J]. Cell, 2020, 181(2): 271-280.e278.
[13]	Ju B, Zhang Q, Ge J, et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection[J]. Nature, 2020, 584(7819): 115-119.
[14]	Pellegrini L, Albecka A, Mallery DL, et al. SARS-CoV-2 infects the brain choroid plexus and disrupts the blood-CSF barrier in human brain organoids[J]. Cell Stem Cell, 2020, 27(6): 951-961.e5.
[15]	Hawrylycz MJ, Lein ES, Guillozet-Bongaarts AL, et al. An anatomically comprehensive atlas of the adult human brain transcriptome[J]. Nature, 2012, 489(7416): 391-399.
[16]	Miller JA, Guillozet-Bongaarts A, Gibbons LE, et al. Neuropathological and transcriptomic characteristics of the aged brain[J]. Elife, 2017, 6: e31126.
[17]	Lukiw WJ, Pogue A, Hill JM. SARS-CoV-2 infectivity and neurological targets in the brain[J]. Cell Mol Neurobiol, 2020: 1-8.
[18]	Hikmet F, Méar L, Edvinsson Å, et al. The protein expression profile of ACE2 in human tissues[J]. Mol Syst Biol, 2020, 16(7): e9610.
[19]	Uhlen M, Karlsson MJ, Zhong W, et al. A genome-wide transcriptomic analysis of protein-coding genes in human blood cells[J]. Science, 2019, 366(6472): eaax9198.
[20]	Qiao J, Li W, Bao J, et al. The expression of SARS-CoV-2 receptor ACE2 and CD147, and protease TMPRSS2 in human and mouse brain cells and mouse brain tissues[J]. Biochem Biophys Res Commun, 2020, Online ahead of print.
[21]	Desforges M, Le Coupanec A, Stodola JK, et al. Human coronaviruses: viral and cellular factors involved in neuroinvasiveness and neuropathogenesis[J]. Virus Res, 2014, 194: 145-158.
[22]	Berth SH, Leopold PL, Morfini GN. Virus-induced neuronal dysfunction and degeneration[J]. Front Biosci (Landmark Ed), 2009, 14: 5239-5259.
[23]	Koyuncu OO, Hogue IB, Enquist LW. Virus infections in the nervous system[J]. Cell Host Microbe, 2013, 13(4): 379-393.
[24]	Netland J, Meyerholz DK, Moore S, et al. Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2[J]. J Virol, 2008, 82(15): 7264-7275.
[25]	Li K, Wohlford-Lenane C, Perlman S, et al. Middle East respiratory syndrome coronavirus causes multiple organ damage and lethal disease in mice transgenic for human dipeptidyl peptidase 4[J]. J Infect Dis, 2016, 213(5): 712-722.
[26]	Brann DH, Tsukahara T, Weinreb C, et al. Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia[J]. Sci Adv, 2020, 6(31): eabc5801.
[27]	Louveau A, Smirnov I, Keyes TJ, et al. Structural and functional features of central nervous system lymphatic vessels[J]. Nature, 2015, 523(7560): 337-341.
[28]	Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19[J]. Lancet, 2020, 395(10234): 1417-1418.
[29]	Moriguchi T, Harii N, Goto J, et al. A first case of meningitis/encephalitis associated with SARS-coronavirus-2[J]. Int J Infect Dis, 2020, 94: 55-58.
[30]	Giacomelli A, Pezzati L, Conti F, et al. Self-reported olfactory and taste disorders in patients with severe acute respiratory coronavirus 2 infection: a cross-sectional study[J]. Clin Infect Dis, 2020, 71(15): 889-890.
[31]	Kaye R, Chang CWD, Kazahaya K, et al. COVID-19 anosmia reporting tool: initial findings[J]. Otolaryngol Head Neck Surg, 2020, 163(1): 132-134.
[32]	Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020, 395(10223): 497-506.
[33]	Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China[J]. Jama, 2020, 323(11): 1061-1069.
[34]	Poyiadji N, Shahin G, Noujaim D, et al. COVID-19-associated acute hemorrhagic necrotizing encephalopathy: imaging features[J]. Radiology, 2020, 296(2): E119-E120.
[35]	Tsai LK, Hsieh ST, Chang YC. Neurological manifestations in severe acute respiratory syndrome[J]. Acta Neurol Taiwan, 2005, 14(3): 113-119.
[36]	Kim JE, Heo JH, Kim HO, et al. Neurological complications during treatment of Middle East respiratory syndrome[J]. J Clin Neurol, 2017, 13(3): 227-233.
[37]	Gu J, Gong E, Zhang B, et al. Multiple organ infection and the pathogenesis of SARS[J]. J Exp Med, 2005, 202(3): 415-424.
[38]	Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression[J]. Lancet, 2020, 395(10229): 1033-1034.
[39]	Murray RS, Brown B, Brian D, et al. Detection of coronavirus RNA and antigen in multiple sclerosis brain[J]. Ann Neurol, 1992, 31(5): 525-533.
[40]	Fazzini E, Fleming J, Fahn S. Cerebrospinal fluid antibodies to coronavirus in patients with Parkinson’s disease[J]. Mov Disord, 1992, 7(2): 153-158.
[41]	Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study[J]. Lancet, 2020, 395(10223): 507-513.

Please choose a citation manager

Content to export